CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to–mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding
Metrics: PDF 1732 views | HTML 3913 views | ?
Naoya Saito1, Naoki Mine1, Donald W. Kufe2, Daniel D. Von Hoff3 and Takumi Kawabe1
1CanBas Co., Ltd., Numazu, Japan
2Dana-Farber Cancer Institute, Harvard School, Boston, MA, USA
3Translational Genomics Research Institute (TGen), Phoenix, AZ, USA
Takumi Kawabe, email: [email protected]
Keywords: CBP501, cell migration, invasion, EMT, calmodulin
Received: February 21, 2017 Accepted: June 05, 2017 Published: June 22, 2017
The anti-cancer agent CBP501 binds to calmodulin (CaM). Recent studies showed that migration and metastasis are inhibited by several CaM antagonists. However, there is no available evidence that CBP501 has similar effects. Here we found that CBP501 inhibits migration of non-small cell lung cancer (NSCLC) cells in vitro, even in the presence of migration inducing factors such as WNT, IL-6, and several growth factors. CBP501 also inhibited epidermal growth factor (EGF) enhanced invasion and the epithelial-to-mesenchymal transition (EMT), and this inhibition was accompanied by (i) suppression of Akt and ERK1/2 phosphorylation, and (ii) suppression of expression of transcription factor Zeb1 and the mesenchymal marker Vimentin. A pull down analysis performed using sepharose-immobilized CaM showed that CBP501 blocks the interaction between CaM and KRas. Furthermore, EGF induced Akt activation and cell migration was effectively suppressed by KRas down-regulation in NSCLC cells. Stable knockdown of KRas also made cells insensitive to CBP501’s inhibition of growth factor-induced migration. Taken together, these results indicate that CBP501 inhibits binding of CaM with KRas and thereby suppresses the PI3K/AKT pathway, migration, invasion and EMT. These findings have identified a previously unrecognized effect of CBP501 on downstream KRas signaling mechanisms involving EMT and invasion, and provide support for the further clinical development of this agent.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.